Ioversol is a diagnostic contrast agent used in various medical imaging procedures, such as angiography, urography, and computed tomographic scans.

Brand Names
Generic Name
DrugBank Accession Number

Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues.2 Iodine has a high atomic density, which gives it the ability to attenuate X-rays.4 The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization of internal structures.2 Ioversol is a highly hydrophilic agent considered to be generally safe4; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use.2

Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left ventriculography.2,4

Small Molecule
Average: 807.115
Monoisotopic: 806.86466
Chemical Formula
  • Ioversol
  • N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
  • Optiray
External IDs
  • MP 328
  • MP-328
  • MP328



As the product Optiray 300, the intra-arterial use of ioversol is indicated for cerebral arteriography and peripheral arteriography in adults, while its intravenous use is indicated for CT imaging of the head and body, venography, and intravenous excretory urography in adults.2

As the product Optiray 320, the intra-arterial use of ioversol is indicated for cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography in adults, and angiocardiography in pediatic patients.2 The intravenous use of this product is indicated for CT imaging of the head and body, venography, and intravenous excretory urography in adults and CT imaging of the head and body, and intravenous excretory urography in pediatric patients.2

As the product Optiray 350, the intra-arterial use of ioversol is indicated for peripheral arteriography coronary arteriography, and left ventriculography in adults, and angiocardiography in pediatic patients.2 The intravenous use of this product is indicated for CT imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (IV-DSA) in adults and CT imaging of the head and body, and intravenous excretory urography in pediatric patients.2

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

The contrast enhancement obtained with ioversol is related to iodine content. Immediately after ioversol is injected, a peak in iodine plasma levels can be detected. However, depending on the organ being imaged, the time to maximum contrast will vary.2 The time to maximum contrast enhancement will range from the time iodine plasma levels reach their highest concentration to one hour after intravenous bolus administration. The delay between a peak in iodine plasma levels and maximum contrast enhancement is partly due to the accumulation of iodine-containing medium within a lesion and outside the blood pool.2

For angiographies, the maximum contrast enhancement of ioversol occurs almost immediately (15-120 seconds). Following rapid intravenous injection, ioversol can be visualized in the renal parenchyma within 30 to 60 seconds. In patients with normal renal function, opacification of the calyces and pelves takes place within 1-3 minutes, with an optimum contrast within 5-15 minutes.2

Mechanism of action

Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs.2 In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region.2 As the product Optiray, ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.3


Healthy volunteers that received 50 and 150 mL of ioversol, had a corresponding Cmax of 1.45 mg/mL and 2.36 mg/mL and a corresponding tmax of 2.0 min and 4.3 min.1 AUC was 1.74 mg⋅hr/mL in healthy volunteers that received 50 mL of ioversol, and 4.43 mg⋅hr/mL in those that received 150 mL.1 The pharmacokinetics of ioversol follow an open two compartment model with first-order elimination.3 Since ioversol is almost completely excreted by the kidney as a parent drug, patients with renal impairment are expected to have a lower elimination rate.2

Volume of distribution

In adults, the volume of distribution of ioversol was 0.26 L/kg body weight, consistent with its extracellular space distribution2.

Protein binding

Ioversol does not bind to serum or plasma proteins.2


Ioversol does not undergo significant metabolism, deiodination or biotransformation.2

Route of elimination

Following intravascular administration, ioversol is excreted mainly through the kidneys.3 Within the first 24 hours, more than 95% of the administered dose is excreted. Urine concentration peaks in the first 2 hours after ioversol is administered.2 Fecal elimination is negligible.3


The elimination half-life was 1.5 hr in healthy volunteers (n=12) receiving 50 and 150 mL of ioversol 68%.2 In patients with renal dysfunction, the elimination half-life of ioversol is prolonged.3


In healthy volunteers that received 50 mL of ioversol, clearance was 156 mL/min, and in those receiving 150 mL of ioversol, clearance was 185 mL/min.1

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

Ioversol overdosage causes life-threatening adverse effects, mainly in the pulmonary and cardiovascular system.2 In case of an overdose, treatment must focus on the support of vital functions and the prompt institution of symptomatic therapy.3 The carcinogenic potential of ioversol has not been evaluated, and non-clinical studies suggest that ioversol is not mutagenic and does not affect fertility.2 The LD50 values in mice and rats are 17 g/kg and 15 g/kg respectively. Developmental toxicity studies were carried out in rats (gestation day 7 to 17) and rabbits (gestation day 6 to 18) given ioversol at the following intravenous doses: 0, 0.2, 0.8, and 3.2 g iodine/kg/day. Adverse effects on embryo-fetal development were not detected in either species, while maternal toxicity was detected in rabbits at 0.8, and 3.2 g iodine/kg/day.2

Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use such as ioversol. These serious adverse reactions include death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.2 Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.3

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirAbacavir may decrease the excretion rate of Ioversol which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Ioversol which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
No interactions found.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
OPTIRAY 300 (Liebel-Flarsheim) / OPTIRAY 320 (Liebel-Flarsheim) / OPTIRAY 350 (Liebel-Flarsheim)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Optiray 160Solution34 %IntravenousTyco Healthcare1992-12-312010-08-05Canada flag
Optiray 160Injection339 mg/1mLIntravascularMallinckrodt Inc.2007-03-232007-03-23US flag
Optiray 160 (ultraject)Solution34 %IntravascularTyco HealthcareNot applicableNot applicableCanada flag
Optiray 240Solution51 % w/vIntravascular; SubarachnoidLiebel Flarsheim Company Llc1996-11-20Not applicableCanada flag
Optiray 240Injection509 mg/1mLIntra-arterial; IntravenousLiebel-Flarsheim Company LLC2012-03-042021-09-15US flag


ATC Codes
V08AB07 — Ioversol
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
Organic compounds
Super Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylaminobenzoic acid and derivatives
Alternative Parents
2-halobenzoic acids and derivatives / 4-halobenzoic acids and derivatives / Anilides / Benzamides / Benzoyl derivatives / Iodobenzenes / Aryl iodides / Vinylogous halides / Tertiary carboxylic acid amides / Secondary alcohols
show 8 more
2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Acylaminobenzoic acid or derivatives / Alcohol / Alkanolamine / Anilide / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Benzamide
show 21 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key


Synthesis Reference

Bailey, AR., et al. (1993). Synthesis of ioversol (U.S. Patent No. 5,489,708). U.S. Patent and Trademark Office.

General References
  1. Wilkins RA, Whittington JR, Brigden GS, Lahiri A, Heber ME, Hughes LO: Safety and pharmacokinetics of ioversol in healthy volunteers. Invest Radiol. 1989 Oct;24(10):781-8. doi: 10.1097/00004424-198910000-00011. [Article]
  2. FDA Approved Products: OPTIRAY (ioversol) injection for intravenous use [Link]
  3. FDA approval package: OPTIRAY (ioversol) injection [Link]
  4. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]: Ioversol [Link]
  5. Toronto Research Chemicals: Ioversol SDS [Link]
PubChem Compound
PubChem Substance
RxList Drug Page Drug Page

Clinical Trials

Clinical Trials


Not Available
Not Available
Dosage Forms
Injection, solution300 MG/ML
Injection, solution320 MG/ML
Injection, solution350 MG/ML
Injection, solutionIntra-arterial; Intravenous160 MG/ML
Injection, solutionIntra-arterial; Intravenous240 MG/ML
Injection, solutionIntra-arterial; Intravenous300 MG/ML
Injection, solutionIntra-arterial; Intravenous320 MG/ML
Injection, solutionIntra-arterial; Intravenous350 MG/ML
SolutionIntravenous741 mg
InjectionIntravascular339 mg/1mL
SolutionIntravenous34 %
SolutionIntravascular34 %
InjectionIntra-arterial; Intravenous509 mg/1mL
SolutionIntravascular; Subarachnoid51 % w/v
LiquidIntravascular240 mg / mL
Injection, solutionParenteral
Injection, solutionIntra-arterial; Intravenous509 mg/ml
SolutionIntra-arterial; Intravenous509 mg/ml
InjectionIntra-arterial; Intravenous636 mg/1mL
Solution300 mg/1ml
SolutionIntravascular64 % w/v
SolutionIntra-arterial; Intravenous636 mg/ml
InjectionIntra-arterial; Intravenous678 mg/1mL
SolutionIntravascular68 % w/v
Solution320 mg/1ml
SolutionIntra-arterial; Intravenous678 mg/ml
InjectionIntra-arterial; Intravenous741 mg/1mL
SolutionIntravascular74 % w/v
Solution350 mg/1ml
InjectionIntravascular741 mg/ml
Injection, solutionIntravascular741 mg/ml
SolutionIntra-arterial; Intravenous741 mg/ml
SolutionIntravenous678 mg
Not Available
Not Available


Experimental Properties
melting point (°C)180-182°CSDS
water solubilityWater solubleFDA label
logP-2.98Howard, PH. Handbook of Physical Properties of Organic Chemicals, Part 1. CRC Press, 1996. p.1395.
Predicted Properties
Water Solubility1.04 mg/mLALOGPS
pKa (Strongest Acidic)11.72Chemaxon
pKa (Strongest Basic)-2.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count8Chemaxon
Polar Surface Area199.89 Å2Chemaxon
Rotatable Bond Count12Chemaxon
Refractivity144.58 m3·mol-1Chemaxon
Polarizability58.31 Å3Chemaxon
Number of Rings1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-0000000790-050c59904af96096455a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0000000900-1cea4c4a6868ebe97251
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0551-0000000920-7d018c61e845a61c1ca6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0btc-0000000900-86708cef6bfe18e517c1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0000004900-8d518fe09fe37ff08dcd
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-3000009700-0b22f4ab91ca271c3f48
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
DeepCCS 1.0 (2019)
DeepCCS 1.0 (2019)
DeepCCS 1.0 (2019)

Drug created at September 29, 2015 22:11 / Updated at June 21, 2024 17:37